New Version of the COVID-19 Treatment Guidelines Now Available

New Version of the COVID-19 Treatment Guidelines Now Available 

The COVID-19 Treatment Guidelines Panel (the Panel) is pleased to announce the release of a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 

Key updates to the Guidelines include: 

• In Prevention of SARS-CoV-2 Infection, the Panel has added a discussion on the Centers for Disease Control and Prevention recommendations for administering an additional dose of an mRNA COVID-19 vaccine to certain people. The Panel has also updated the information on vaccine-associated adverse effects, including myocarditis, pericarditis, and Guillain-Barré syndrome. A new subsection provides the Panel's recommendations and rationale for using either bamlanivimab plus etesevimab or casirivimab plus imdevimab as post-exposure prophylaxis for those who have a history of exposure to individuals with SARS-CoV-2 infection and who are at high risk of progression to serious disease if they acquire the infection.
• A new subsection has been added to Clinical Spectrum of SARS-CoV-2 Infection to discuss coinfections, reactivation of latent infection, nosocomial infections, and opportunistic fungal infections that may occur in patients with COVID-19.
• The text and figure in Therapeutic Management of Nonhospitalized Adults With COVID-19 have been updated to add bamlanivimab plus etesevimab as an anti-SARS-CoV-2 monoclonal antibody (mAb) combination option for the treatment of nonhospitalized patients with mild to moderate COVID-19 who are at high risk of progression to severe disease.
• The recommendations and rationale for performing awake prone positioning in nonmechanically ventilated adults have been updated in Oxygenation and Ventilation.
• Anti-SARS-CoV-2 Monoclonal Antibodies now includes bamlanivimab plus etesevimab as a treatment option for nonhospitalized patients with mild to moderate COVID-19 who are at high risk for clinical progression. The information on the in vitro susceptibility of circulating variants to these mAbs and the potential activities of these mAbs against variants has been updated.
• In Interleukin-1 Inhibitors, the Panel recommends against the use of canakinumab for the treatment of COVID-19, except in a clinical trial. This section also now includes a detailed discussion of the data on the use of anakinra from the SAVE-MORE, REMAP-CAP, and CORIMUNO-ANA-1 trials.
• Interleukin-6 Inhibitors has been updated to incorporate results from the sarilumab arm of the REMAP-CAP trial, an open-label, adaptive-platform randomized trial in patients with COVID-19 who were receiving invasive or noninvasive mechanical ventilation or cardiovascular support.
• Kinase Inhibitors: Janus Kinase Inhibitors and Bruton’s Tyrosine Kinase Inhibitors now includes a detailed discussion of the COV-BARRIER trial of baricitinib and the STOP-COVID trial of tofacitinib.

For a complete list of updates, please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.